Question 1

What are the most cited papers from Asarina Pharma (Sweden)?

Accepted Answer

The most cited paper from Asarina Pharma (Sweden) is "Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial" (Marie Bixo, Karin Ekberg, Inger Sundström Poromaa et al., 2017), with 132 citations. Next come "Acceleration of Amyloidosis by Inflammation in the Amyloid-Beta Marmoset Monkey Model of Alzheimer’s Disease" (78) and "GR3027 antagonizes GABA A receptor-potentiating neurosteroids and restores spatial learning and motor coordination in rats with chronic hyperammonemia and hepatic encephalopathy" (76).

Question 2

Which research topics does Asarina Pharma (Sweden) publish most on?

Accepted Answer

By volume in 2022-now: Neuroscience and Neuropharmacology Research, Neuroinflammation and Neurodegeneration Mechanisms, Chronic Myeloid Leukemia Treatments and Liver Disease Diagnosis and Treatment.

Question 3

Which fields of science does Asarina Pharma (Sweden) work in?

Accepted Answer

In all years, 46% of research at Asarina Pharma (Sweden) is in Health Sciences, 38% in Life Sciences. Its largest fields are Medicine (45%), Neuroscience (29%), Chemistry (8%). It does 1.6× the world's share of Life Sciences.

Question 4

Is Asarina Pharma (Sweden)'s research output growing?

Accepted Answer

Output in 2022-2025 was 876% higher than in 2018-2021.